% 0期刊文章% Caterina Lapucci %一个西尔维亚Rebella Francesco浅杯% %一个Luca Roccatagliata % Ncola Mavilio % Giacomo Boffa %一个埃尔韦拉Sbragia %一个伊丽莎白·曼尼科洛Bruschi % %一个西蒙娜玛丽亚Cellerino % Schiavi %马蒂尔德Inglese % T中央静脉标志和先进的扩散磁共振成像来区分从comorbidities-related白质脱髓鞘病变的多发性硬化症患者(p1 - 1. -虚拟)% D J神经病学2022% % P V 98% 2534% N % X 18补充目的:(i)来评估风险因素的影响(RFs)小血管疾病(计算)和偏头痛的百分比中央静脉标志(CVS) CVS + /−病变(% CVS + /−)检测到整个大脑和多发性硬化(MS)患者的条件;首页(2)调查是否球形意味着技术(SMT)可能区分CVS +从CVS−病变。背景:并发症的影响在CVS % + /−女士调查诊断和监测一直不佳。设计/方法:120 MS患者(女55%,名RRMS 70%),分层在4岁组(1组(18 - 30年),2组(31 - 45岁年),3(46-56年)组,4组(57 - 77年),每组n = 30)执行大脑3 t-mri扫描协议包括3 depi-t2 *三和multishell扩散图像。CVS评估进行天赋*图像。广义估计方程(GEE)模型是用来比较SMT指标之间CVS +和CVS−病变。结果:总共5303白质(WM)病变选择CVS评估(中位数:38病变/病人)。CVS + 3645 (68.7%)。病灶体积之间不同的CVS +和CVS−病变在整个大脑(中位数:1292 mm3 vs 224 mm3分别;在大脑所有的4 p < 0.001)和条件(深/皮层下WM、室,juxtacortical infratentorial; (p<0.001 for all]. The median %CVS+ decreased from Group 1 to Group 4 (from 79.1% to 57.7%). Deep/subcortical WM was the only subregion in which CVS+ lesion number was not significantly higher than CVS− counterpart. Age and migraine were predictors of a lower %CVS+. CVS+ showed higher SMT-EXTRAMD (p=0.001), higher SMT-EXTRATRANS (p=0.001) and lower SMT-INTRA (p=0.02) than CVS− lesions.Conclusions: Age was the strongest predictor of %CVS+. CVS+ lesions were characterized by a more severe degree of inflammation, demyelination and fiber disruption. A careful evaluation of comorbidities during CVS assessment for MS diagnosis and monitoring should be mandatory, to avoid misleading interpretations and inappropriate therapeutic strategies.Disclosure: Caterina Lapucci has nothing to disclose. Francesco Tazza has nothing to disclose. Miss Rebella has nothing to disclose. Dr. Mavilio has nothing to disclose. Mr. Boffa has nothing to disclose. Elvira Sbragia has nothing to disclose. Nicolo Bruschi has nothing to disclose. Elisabetta Mancuso has nothing to disclose. Maria Cellerino has nothing to disclose. Simona Schiavi has nothing to disclose. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SANOFI GENZYME. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIOGEN. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVARTIS. Dr. Inglese has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for MERCK-SERONO. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Dr. Inglese has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MS Journal. The institution of Dr. Inglese has received research support from TEVA NEUROSCIENCE. %U